
- Oncology NEWS International Vol 5 No 9
- Volume 5
- Issue 9
FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer
ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia (pamidronate disodium for injection) for the treatment of patients with osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy.
ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia(pamidronate disodium for injection) for the treatment of patientswith osteolytic bone metastases of breast cancer, in conjunctionwith standard antineoplastic therapy.
The drug has been on the market since 1991 and is also indicatedfor the treatment of osteolytic bone lesions of multiple myeloma,moderate-to-severe hypercalcemia of malignancy, and moderate-to-severePaget's disease.
Articles in this issue
about 29 years ago
Multimodality Approaches Used in Esophageal Cancerabout 29 years ago
Talking With Your Doctor About Cancer and Its Therapyabout 29 years ago
Guttman Institute Reopens With Expanded Screening Servicesabout 29 years ago
Weight Gain, Not Fat Intake, Increases Breast Cancer Riskabout 29 years ago
Knowing When to Bow Out Gracefullyabout 29 years ago
Chemo Appears Not To Raise Birth Defect Risk in Offspringabout 29 years ago
Discovery of HIV-1 Protein Structure Could Lead to New Therapiesabout 29 years ago
'Friends of Cancer Research' Will Lead New Public Education Campaignabout 29 years ago
Cost of the New HIV Therapies Creates a Doctor's DilemmaNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.